AU2013349801B2 - Method for indicating a presence or non-presence of aggressive prostate cancer - Google Patents
Method for indicating a presence or non-presence of aggressive prostate cancer Download PDFInfo
- Publication number
- AU2013349801B2 AU2013349801B2 AU2013349801A AU2013349801A AU2013349801B2 AU 2013349801 B2 AU2013349801 B2 AU 2013349801B2 AU 2013349801 A AU2013349801 A AU 2013349801A AU 2013349801 A AU2013349801 A AU 2013349801A AU 2013349801 B2 AU2013349801 B2 AU 2013349801B2
- Authority
- AU
- Australia
- Prior art keywords
- snppc
- pca
- category
- biomarker
- composite value
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Medicinal Chemistry (AREA)
- Evolutionary Biology (AREA)
- Medical Informatics (AREA)
- Theoretical Computer Science (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1251312 | 2012-11-20 | ||
| SE1251312-3 | 2012-11-20 | ||
| SE1350600-1 | 2013-05-16 | ||
| SE1350600 | 2013-05-16 | ||
| PCT/EP2013/074259 WO2014079865A1 (en) | 2012-11-20 | 2013-11-20 | Method for indicating a presence or non-presence of aggressive prostate cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2013349801A1 AU2013349801A1 (en) | 2015-05-28 |
| AU2013349801B2 true AU2013349801B2 (en) | 2019-03-07 |
Family
ID=49619938
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2013349801A Active AU2013349801B2 (en) | 2012-11-20 | 2013-11-20 | Method for indicating a presence or non-presence of aggressive prostate cancer |
Country Status (14)
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013134179A2 (en) | 2012-03-05 | 2013-09-12 | Arctic Partners Oy | Methods and apparatuses for predicting risk of prostate cancer and prostate gland volume |
| RU2669809C2 (ru) | 2012-11-20 | 2018-10-16 | Пхадиа Аб | Способ прогноза для индивидуумов с раком предстательной железы |
| RU2720148C9 (ru) | 2014-03-11 | 2020-09-28 | Пхадиа Аб | Способ обнаружения солидной злокачественной опухоли |
| ES2964706T3 (es) | 2014-03-28 | 2024-04-09 | Opko Diagnostics Llc | Composiciones y métodos relacionados con el diagnóstico de cáncer de próstata |
| US12326453B2 (en) * | 2014-03-28 | 2025-06-10 | Opko Diagnostics, Llc | Compositions and methods for active surveillance of prostate cancer |
| CA2979559A1 (en) | 2015-03-27 | 2016-10-06 | Opko Diagnostics, Llc | Prostate antigen standards and uses thereof |
| US9858665B2 (en) * | 2015-04-03 | 2018-01-02 | Regents Of The University Of Minnesota | Medical imaging device rendering predictive prostate cancer visualizations using quantitative multiparametric MRI models |
| WO2016176529A1 (en) * | 2015-04-29 | 2016-11-03 | Opko Diagnostics, Llc | Compositions and methods for active surveillance of prostate cancer |
| WO2017164699A1 (ko) * | 2016-03-24 | 2017-09-28 | 서울대학교병원 (분사무소) | 전립선암과 관련된 단일염기다형성 및 이를 이용한 유전 위험도 점수의 개발 |
| DK3270163T3 (en) * | 2016-07-15 | 2018-11-19 | Proteomedix Ag | PROCEDURE FOR DETECTING PROTEINS IN HUMAN SAMPLES AND APPLICATIONS OF SUCH PROCEDURES |
| FI3577237T3 (fi) * | 2017-02-01 | 2023-08-29 | Phadia Ab | Menetelmä eturauhassyövän läsnäolon tai puuttumisen osoittamiseksi henkilöillä, joilla on tiettyjä ominaisuuksia |
| KR102093453B1 (ko) * | 2018-01-08 | 2020-03-25 | (주)인실리코젠 | 체형 및 대사 감수성 snp 마커 및 진단정보 제공방법 |
| WO2019144112A1 (en) | 2018-01-22 | 2019-07-25 | Phadia Ab | Method for the harmonization of assay results |
| IT201800021394A1 (it) * | 2018-12-28 | 2020-06-28 | Daniela Terracciano | Metodo in vitro per la diagnosi del cancro alla prostata |
| US11633146B2 (en) | 2019-01-04 | 2023-04-25 | Regents Of The University Of Minnesota | Automated co-registration of prostate MRI data |
| US11631171B2 (en) | 2019-01-10 | 2023-04-18 | Regents Of The University Of Minnesota | Automated detection and annotation of prostate cancer on histopathology slides |
| CN109628564B (zh) * | 2019-02-25 | 2022-02-01 | 北京市理化分析测试中心 | 一种用于检测snp多态性的引物组和利用引物组检测snp多态性的方法 |
| KR102068666B1 (ko) * | 2019-02-28 | 2020-02-11 | 주식회사 프로카젠 | 인종 별 전립선암 유전위험점수 산출장치, 산출방법 및 이의 기록매체 |
| KR102371654B1 (ko) * | 2019-02-28 | 2022-03-08 | 주식회사 프로카젠 | 유전 변이의 개수에 따른 예측력을 고려한 전립선암 유전위험점수 산출장치, 산출방법 및 이의 기록매체 |
| KR102371655B1 (ko) * | 2019-02-28 | 2022-03-08 | 주식회사 프로카젠 | 각 유전 변이 정보에 개별적인 가중치를 부여한 전립선암 유전위험점수 산출장치, 산출방법 및 이의 기록매체 |
| KR102068667B1 (ko) * | 2019-02-28 | 2020-01-21 | 주식회사 프로카젠 | 전립선암 유전위험점수 산출장치, 산출방법 및 이의 기록매체 |
| IT202000029948A1 (it) * | 2020-12-04 | 2022-06-04 | Nib Biotec S R L | Metodo per la diagnosi di tumore alla prostata in pazienti in differente fascia di età |
| JP7641532B2 (ja) | 2020-08-28 | 2025-03-07 | 国立研究開発法人理化学研究所 | 前立腺がんの検査方法 |
| GB2599198B (en) * | 2021-06-15 | 2022-12-07 | A3P Biomedical Ab | A method for determining an appropriate time interval for further diagnostic testing for prostate cancer |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010012823A1 (fr) * | 2008-08-01 | 2010-02-04 | Commissariat A L'energie Atomique | Procede de prediction pour le depistage, le pronostic, le diagnostic ou la reponse therapeutique du cancer de la prostate et dispositif permettant la mise en oeuvre du procede |
| WO2010081240A1 (en) * | 2009-01-19 | 2010-07-22 | Miraculins Inc. | Diagnostic assays for prostate cancer using psp94 and psa biomarkers |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030219840A1 (en) | 2002-05-24 | 2003-11-27 | Mikolajczyk Stephen D. | Method of analyzing proenzyme forms of prostate specific antigen in serum to improve prostate cancer detection |
| WO2010093939A2 (en) | 2009-02-12 | 2010-08-19 | Dana-Farber Cancer Institute, Inc. | Predicting and treating prostate cancer |
| WO2011150515A1 (en) | 2010-06-01 | 2011-12-08 | Universite Laval | Prognostic markers for prostate cancer recurrence |
| EP2611943B1 (en) * | 2010-09-03 | 2017-01-04 | Wake Forest University Health Sciences | Methods and compositions for correlating genetic markers with prostate cancer risk |
| US20120202888A1 (en) | 2010-10-08 | 2012-08-09 | The Brigham And Women's Hospital, Inc. | Biomarkers of prostate cancer and predicting mortality |
| US20120150032A1 (en) * | 2010-12-13 | 2012-06-14 | Julius Gudmundsson | Sequence Variants Associated with Prostate Specific Antigen Levels |
| EP2850432A2 (en) | 2012-05-16 | 2015-03-25 | Phadia AB | Method for indicating the presence or non-presence of prostate cancer |
| RU2669809C2 (ru) | 2012-11-20 | 2018-10-16 | Пхадиа Аб | Способ прогноза для индивидуумов с раком предстательной железы |
-
2013
- 2013-11-20 AU AU2013349801A patent/AU2013349801B2/en active Active
- 2013-11-20 DK DK13792689.5T patent/DK2922967T3/en active
- 2013-11-20 JP JP2015542308A patent/JP2016503301A/ja active Pending
- 2013-11-20 EP EP13792689.5A patent/EP2922967B1/en active Active
- 2013-11-20 BR BR112015011359-1A patent/BR112015011359B1/pt not_active IP Right Cessation
- 2013-11-20 RU RU2015124054A patent/RU2675370C2/ru active
- 2013-11-20 EP EP17210720.3A patent/EP3327146A1/en not_active Withdrawn
- 2013-11-20 US US14/443,970 patent/US10431326B2/en active Active
- 2013-11-20 ES ES13792689.5T patent/ES2667326T3/es active Active
- 2013-11-20 MY MYPI2015701578A patent/MY182773A/en unknown
- 2013-11-20 KR KR1020157015113A patent/KR20150110477A/ko not_active Ceased
- 2013-11-20 CA CA2891392A patent/CA2891392C/en active Active
- 2013-11-20 WO PCT/EP2013/074259 patent/WO2014079865A1/en active Application Filing
- 2013-11-20 CA CA3092807A patent/CA3092807C/en active Active
-
2015
- 2015-05-10 IL IL238724A patent/IL238724A0/en unknown
- 2015-05-18 ZA ZA2015/03460A patent/ZA201503460B/en unknown
-
2018
- 2018-10-04 JP JP2018189147A patent/JP2019049559A/ja active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010012823A1 (fr) * | 2008-08-01 | 2010-02-04 | Commissariat A L'energie Atomique | Procede de prediction pour le depistage, le pronostic, le diagnostic ou la reponse therapeutique du cancer de la prostate et dispositif permettant la mise en oeuvre du procede |
| WO2010081240A1 (en) * | 2009-01-19 | 2010-07-22 | Miraculins Inc. | Diagnostic assays for prostate cancer using psp94 and psa biomarkers |
Non-Patent Citations (1)
| Title |
|---|
| MARKUS ALY ET AL, "Polygenic Risk Score Improves Prostate Cancer Risk Prediction: Results from the Stockholm-1 Cohort Study", EUROPEAN UROLOGY, vol. 60, no. 1, doi:10.1016/J.EURURO.2011.01.017, 2011, pages 21 - 28 * |
Also Published As
| Publication number | Publication date |
|---|---|
| RU2015124054A (ru) | 2017-01-10 |
| US10431326B2 (en) | 2019-10-01 |
| EP3327146A1 (en) | 2018-05-30 |
| US20150317431A1 (en) | 2015-11-05 |
| CA3092807C (en) | 2024-02-27 |
| ZA201503460B (en) | 2018-11-28 |
| CA3092807A1 (en) | 2014-05-30 |
| BR112015011359B1 (pt) | 2022-12-06 |
| CA2891392A1 (en) | 2014-05-30 |
| DK2922967T3 (en) | 2018-04-16 |
| EP2922967A1 (en) | 2015-09-30 |
| ES2667326T3 (es) | 2018-05-10 |
| CA2891392C (en) | 2020-11-03 |
| MY182773A (en) | 2021-02-05 |
| JP2019049559A (ja) | 2019-03-28 |
| BR112015011359A2 (pt) | 2017-07-11 |
| WO2014079865A1 (en) | 2014-05-30 |
| CN105051206A (zh) | 2015-11-11 |
| EP2922967B1 (en) | 2018-01-03 |
| KR20150110477A (ko) | 2015-10-02 |
| JP2016503301A (ja) | 2016-02-04 |
| AU2013349801A1 (en) | 2015-05-28 |
| RU2675370C2 (ru) | 2018-12-19 |
| IL238724A0 (en) | 2015-06-30 |
| HK1215594A1 (en) | 2016-09-02 |
| BR112015011359A8 (pt) | 2019-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2013349801B2 (en) | Method for indicating a presence or non-presence of aggressive prostate cancer | |
| US20200010912A1 (en) | Prognostic method for individuals with prostate cancer | |
| RU2720148C9 (ru) | Способ обнаружения солидной злокачественной опухоли | |
| US20150094221A1 (en) | Method for Indicating the Presence or Non-Presence of Prostate Cancer | |
| JP2022179483A (ja) | 特定の特徴を有する個体において前立腺癌の存在または不存在を示すための方法 | |
| HK1215594B (en) | Method for indicating a presence or non-presence of aggressive prostate cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| PC | Assignment registered |
Owner name: A3P BIOMEDICAL AB Free format text: FORMER OWNER(S): PHADIA AB |